Transglutaminase 6 antibodies are not yet mainstream in neuro-coeliac disease Worldwide 1% of the population suffers from a gluten related disorder (GRD) that severely impacts ones life, and no therapeutic treatment, except a gluten-free diet, is available. GRD's are a group of immune mediated diseases triggered by the ingestion of gluten. Well known is coeliac disease (CD) that presents with enteropathy. Some patients present exclusively with extra-intestinal manifestations such as skin involvement in dermatitis herpetiformis (DH). Over the last fifty years, patients with gluten sensitivity presenting with neurological symptoms have been described more and more. These symptoms include e.g. cerebellar ataxia and peripheral neuropathies and were thus far considered to be a rare manifestation of GRD. Thus, the diagnosis of neuro-coeliac disease is not yet based on objective and verifiable clinical and/or pathological criteria set by international working groups, such as those of the international Society for the Study of Celiac Disease, the European Society of Pediatric Gastroenterology and Nutrition or Neurological Societies. It would be recommended that groups working on neuro-coeliac disease bundle their forces to obtain a large international cohort of patients to standardize the clinical and pathological picture of this disease. The Sheffield group, led by professor Hadjivassiliou, is one of the leading groups working on neuro-coeliac disease. In the past they have shown that cerebellar ataxia in gluten sensitive patients coincides with white matter abnormalities and neuropathology. Moreover, they found that Transglutaminase (TG) 6 antibodies are overrepresented in the serum of these patients [1]. Serum markers in CD include the presence of TG2 antibodies, and in DH elevated levels of TG3 antibodies can be found [2,3]. In a previous issue of this journal, Panagiotis Zis et al. present a cross-sectional study on 28 patients with peripheral neuropathies, i.e. sensory ganglionopathy, symmetrical axonal neuropathy or mononeuritis multiplex. The notion that TG6 antibodies were enhanced in cerebellar ataxia patients, and that TG6 is considered to be a Transglutaminase more specific to the central nervous system, they now questioned whether TG6 antibodies were elevated in gluten sensitive patients with peripheral neuropathy. The prevalence of TG6 antibodies was 50% compared to 4% in the healthy population, suggesting that TG6 involvement is not confined to the central nervous system alone, but also can affect the peripheral nervous system. In addition, in CD more than 95% of patients share the HLA DQ2 or DQ8 haplotype, whereas of the patients in this study only 62% shared those HLA haplotypes. Moreover, TG2 antibodies were also elevated in this population [4]. As mentioned the so-called neuro-coeliac disease manifestations are not well studied by neurologists and neuroscientists and